Navigation Links
New therapy found for rare lung disorder
Date:3/16/2011

ing lung function in women with LAM."

McCormack says LAM cells isolated from lung lesions have TSC mutations and exhibit activation of a key sirolimus-sensitive growth pathway. When exposed to the drug in culture, the growth of LAM cells is stopped.

Experiments in TSC animal models have also demonstrated that sirolimus shrinks tumors in the liver and kidneys.

The MILES study was conducted within the National Institutes of Health (NIH)-supported Rare Lung Diseases Consortium, led by UC and Cincinnati Children's physician and pulmonary biologist Bruce Trapnell, MD, and co-directed by McCormack, and involved 13 institutions from around the world. Data was reported using Internet-based systems connected to a centralized, Internet-based data coordinating center headed by Jeffrey Krischer, MD, at the University of South Florida, Tampa.

"The trial included a screening visit and a year-long double blind, placebo-controlled treatment period, followed by a year of observation," says McCormack.

All eligible participants were female, aged 18 years or older and had a confirmed diagnosis of LAM with abnormal lung function.

Patients meeting the criteria were randomly assigned to either receive an initial dose of oral sirolimus at 2 milligrams per day or a matched placebo, and sirolimus levels were measured at each follow-up visit. Results were revealed only to an independent medical monitor who made dosing recommendations to maintain serum levels within a pre-specified target range.

A total of 89 patients with LAM were enrolled in the United States, Canada and Japan. Patients underwent baseline lung function testing, and lung function and exercise outcomes were measured over the course of six visits in the first year. Participants were also given questionnaires to determine how their symptoms changed throughout the course of the study.

Researchers found that sirolimus stabilized lung function and was associ
'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Sirolimus therapy alleviates symptoms of lung disease LAM
2. Research study explores gene therapy treatment to reduce symptoms of Parkinsons disease
3. University Hospitals Case Medical Center testing innovative heat therapy for premature ejaculation
4. Ohio State study: Targeted ovarian cancer therapy not cost-effective
5. Stroke patients benefit from family involvement in exercise therapy
6. Extra Tests Not a Deterrent to Experimental Cancer Therapy
7. Gene Therapy Against HIV Not a Proven Cure, Experts Say
8. WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves
9. BUSM study shows chemoradiotherapy prior to surgery improves survival
10. Fish oil fights weight loss due to chemotherapy
11. Lack of health insurance limits hepatitis C patients access to latest antiviral therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... August 01, 2014 Stryker hip ... of the 2012 Rejuvenate and ABG II Modular-Neck ... New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... proceeding, the Court has issued a Final ... and all hard copy and electronic materials produced ...
(Date:8/1/2014)... August 01, 2014 Summer is here, and ... active during the summer, and they can be a pain ... ready to help all their customers get rid of ticks ... and 6,000 eggs in the summer, which is why they ... in tall grass and woodland areas and carry a number ...
(Date:8/1/2014)... Washington, DC (PRWEB) August 01, 2014 ... Mike Thompson (D-CA), Gregg Harper (R-MS), and Peter ... H.R. 5380, the Medicare Telehealth Parity Act of ... "We fully support this effort to improve healthcare ... Linkous, chief executive officer of ATA. "These cost-saving ...
(Date:8/1/2014)... The "Antimicrobial Coatings Market by Type (Silver, ... Dioxide, and Zinc Omadine), Application (Indoor air/HVAC, Medical, ... Textiles, and others), & Geography (North America, Europe, ... to 2018" analyzes the Antimicrobial Coatings Market with ... the diverse geographical regions. , Browse 49 market ...
(Date:8/1/2014)... The North America Endpoint Security Market report defines ... America with analysis and forecast of revenue. This market ... 2014 to $4.77 billion by 2019, at a CAGR ... the TOC of the North America Endpoint Security Market ... provided. It also provides a glimpse of the segmentation ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... , ARLINGTON, Va., Oct. 8 The U.S. Centers for ... TriData division, which specializes in public safety research and ... prevention practices in 10 nations. , The study ... reductions in fire deaths and injuries in these nations. ...
... Greater Surface Disinfection to Combat Bad Hygiene , ARLINGTON, Va., ... standing in the lunch line? Or sneeze loudly into the ... (96 percent) have seen you do things like this -- and ... , Even with heightened concerns during this year,s flu season, ...
... ... device, a rapid phase transition gel used in the treatment of Kidney Stones. ... Woburn, Massachusetts (PRWEB) ... alliance with Boston Scientific Corporation (NYSE: BSX) regarding Pluromed,s BackStop™ product, a device used ...
... ... media, cell separation products and ancillary reagents for life science research, is pleased to ... ... 8, 2009 -- STEMCELL Technologies Inc. (STEMCELL), a leader in specialty cell culture media, ...
... ... announces the release of their Mediterranean Diet Resveratrol Formula. , ... Plainview, NY (PRWEB) October ... dietary supplements, announces the release of their Mediterranean Diet Resveratrol Formula., , ,Purity,s ...
... , ... week, the Cheney Research Web site ( www.cheneyresearch.com ) is a multimedia medical Web ... cutting-edge medical concepts and therapies developed at the Cheney Clinic and conveyed in part ... ...
Cached Medicine News:Health News:International Study Finds New Best Practices to Reduce Fire Casualties 2Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 2Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 3Health News:Pluromed, Inc. Signs Agreement with Boston Scientific 2Health News:Pluromed, Inc. Signs Agreement with Boston Scientific 3Health News:STEMCELL Technologies Inc. Announces Direct Distribution to Spain 2Health News:Purity Products Releases Their Brand New Mediterranean Diet Resveratrol Formula 2Health News:Chronic Fatigue Syndrome and Stem Cell Therapy - Latest Research Available at CheneyResearch.com 2Health News:Chronic Fatigue Syndrome and Stem Cell Therapy - Latest Research Available at CheneyResearch.com 3
(Date:8/1/2014)... , Aug. 1, 2014 RoundTable ... focused exclusively on the healthcare industry, announced today ... The Lubrizol Corporation ("Lubrizol"). Lubrizol, a Berkshire Hathaway ... and supplies technologies to customers in the global ... transaction were not disclosed. Vesta is ...
(Date:8/1/2014)... Minn. , Aug. 1, 2014 ... medical technologies company, announced today that it has ... held manufacturer of cardiorespiratory diagnostic products based in ... MediSoft has served the European cardiorespiratory diagnostics market ... 2013 revenues of approximately €4.7 million ($6.3 million) ...
(Date:8/1/2014)... , Aug. 1, 2014 Dyadic International, Inc. ... and proprietary technologies are used to develop, manufacture and ... chemical, biopharmaceutical and industrial enzyme industries, announced today that ... quarter ended June 30, 2014 after market close on ... call that day at 5:00 p.m. Eastern Time to ...
Breaking Medicine Technology:RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Multi-Tier Shaker...
... The Thermo Labsystems Wellmix is a ... and time settings. The shaking speed is ... shaking frequency, high speed and a small ... assays. The shaking time is quick and ...
Medicine Products: